Novo Nordisk Pricing Erodes Telehealth Moats

Novo Nordisk reset the source of advantage from drug access to patient experience almost overnight. Once Wegovy moved to a manufacturer controlled $499 cash price across Ro, Hims & Hers, and LifeMD in April 2025, none of those platforms could claim a unique supply edge. What remained was the front end, how easily a patient gets evaluated, prescribed, monitored, and kept on therapy over months.

• Ro still had more to sell than a prescription. Its weight loss business bundled clinician review, labs, dose changes, messaging, and pharmacy routing, and Ro estimated GLP-1 drove about $370M of its 2024 revenue. That matters because branded drug pricing became standardized, but care delivery and retention economics did not.
  1 sacra 2 sacra
• This followed the end of the compounding window. As shortages eased and Novo pushed patients into NovoCare Pharmacy, telehealth companies lost the unusually high margin they had earned from compounded semaglutide and became distribution and care layers on top of manufacturer supply instead.
  2 sacra 4 novocare 5 globenewswire
• The moat proved even weaker than it looked in April 2025. Novo terminated its Hims & Hers collaboration on June 23, 2025, showing that these channels were not only price standardized, but also dependent on manufacturer approval and channel rules that could change quickly.
  6 hims 7 globenewswire

The next phase shifts from who can get the drug to who can justify staying in the middle. Ro is heading toward a market where winning depends on lower acquisition cost, better adherence, tighter clinical workflows, and eventually employer and payer contracts that reward outcomes rather than access alone.